good morning america semaglutide For the first time, Medicare will cover GLP-1s for obesity-related weight loss, without any other medical conditions. Starting Wednesday, eligible Medicare beneficiaries can receive GLP-1s for obesity for $50 per month by New study finds weight loss

This decision was based on data suggesting that manufacturers could now meet the current and projected demand for injectable semaglutide, the active ingredient in popular medications like Ozempic and Wegovy

People taking these medicines may require dose adjustments to their existing treatments under medical supervision

For others, very high protein does produce enough gluconeogenesis to reduce ketone production

Still, its best to view these numbers with caution. Larger studies over longer periods of time are needed to confirm and clarify the effects of GLP-1 drugs on peoples use of alcohol and other harmful substances, including tobacco and opioids.

Novo Nordisk, the manufacturer who makes Wegovy, lists the price of Wegovy at $1,349.02 for a 28-day supply , or about $17,585 a year, without insurance